Shanghai Cell Therapy Group Co. Ltd. ("SH Cell"), a leading company in China's cell therapy industry, officially announced its completion of series C fund raising led by China Pacific Life Insurance Co. Ltd., Haier Capital and China Industrial Asset Management Limited with the total investment amounted to RMB925 million in December, 2018, which is the largest fund raising recently completed by cell therapy industry.
As the leading company in China's cell therapy industry, SH Cell is the first platform company to build a closed loop of the "new drug research and development, tumor clinical treatment and cell preservation services" industry chain. SH Cell has outstanding advantages in the clinical transformation of cell therapy. It has been investing in basic research of immune cell technology for many years, and has made major breakthroughs in its research and development of multiple cell therapeutic medicines.
As the legal adviser for SH Cell, Llinks provided legal services for its series C fund raising.
